Skip navigation

News Summary: 5 more countries OK Pfizer's Xeljanz

NEW APPROVALS: Five more countries will allow sales of Pfizer Inc.'s new twice-a-day pill for controlling rheumatoid arthritis, Xeljanz: Russia, Argentina, Kuwait, United Arab Emirates and Switzerland. Full story

Lilly says arthritis pill effective in mid-stage study

(Reuters) - Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment. Full story

Pfizer results fall short; company trims profit forecast

(Reuters) - Pfizer Inc reported lower-than-expected quarterly earnings and revenue, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending its shares down 3 percent. Full story

Pfizer arthritis drug rejected by European regulators

(Reuters) - European regulators declined to approve marketing of Pfizer Inc's new rheumatoid arthritis treatment Xeljanz, citing the risks of the drug compared with its potential benefit, the company said on Thursday. Full story

Roche says Japan approves new formulation of arthritis drug

ZURICH (Reuters) - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra. Full story

Study finds no link between pollution and rheumatoid arthritis

(Reuters) - Some research has suggested a connection between exposure to air pollution and the risk of developing rheumatoid arthritis, but a large study of U.S. nurses has found no link. Full story

Sponsored Links


Study finds no rheumatoid arthritis, pollution link

AbbVie seeks to stop EU agency releasing drug data

Ablynx books success with arthritis drug study

FDA panel favors Pfizer's new arthritis drug

Doc's arthritis struggle shows illness' severity

Having a baby makes mom's body turn on itself


  May 9: Nightly News Wednesday broadcast

Obama backs same-sex marriage; America’s changing attitude toward gay marriage; End of an era: Richard Lugar loses; Elizabeth Edwards ‘very upset’ about donor; New drug for rheumatoid arthritis; Girls reporting twice as many concussions as boys; Vidal Sassoon, hair-care pioneer, has died; Rememberin